Frequency of pre-treatment may not increase the immune-related adverse events of RCC patients treated with nivolumab

Nivolumab has shown good prognosis in renal cell carcinoma (RCC) patients previously treated with targeted therapy. We aimed to study irAE (immune-related adverse event) due to nivolumab and numbers of previous treatment lines in RCC patients. Between October 2016 and November 2019, 114 patients wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizutani, Kosuke, Ito, Toshiki, Takahara, Kiyoshi, Ando, Ryosuke, Ishihara, Takuma, Yasui, Takahiro, Shiroki, Ryoichi, Miyake, Hideaki, Koie, Takuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
7300
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021322/
https://www.ncbi.nlm.nih.gov/pubmed/33787647
http://dx.doi.org/10.1097/MD.0000000000025402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021322/
https://www.ncbi.nlm.nih.gov/pubmed/33787647
http://dx.doi.org/10.1097/MD.0000000000025402

Ejemplares similares